Enhancing Care Management of the Chronically Ill Through Medication Management and Adherence Harry Leider, MD, MBA, FACPE Chief Medical Officer XLHealth.

Slides:



Advertisements
Similar presentations
Today’s Agenda Discuss the prevention and management of cardiovascular complications of diabetes Mention the other complications along with prevention.
Advertisements

Employee Wellness Committee – January 29, 2009 Lee Covella / Paul Hackleman / Bill Tugaw.
© HealthFitness 2012 Integrated Health Coaching: The Next Generation in Health Behavior Change Management Dennis Richling, Chief Medical and Wellness Officer.
Disease State Management The Pharmacist’s Role
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Innovative Pharmacy Services Jann B. Skelton, RPh, MBA Vice President of Operations MEDICA.
School Employee Health Care Board Conference Joe San Filippo Chief Health Care Strategist Nationwide Better Health.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Canadian Diabetes Association Clinical Practice Guidelines Dyslipidemia Chapter 24 G. B. John Mancini, Robert A. Hegele, Lawrence A. Leiter.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
April 2009 Netta Conyers-Haynes, Principal Consultant, Communications Kaiser Permanente's Aspirin, Lisinopril, Lovastatin (ALL) Program: From Consensus.
Integrated Disease Management at HealthPartners Health Care Transformation Task Force Meeting August 16, 2007 N. Marcus Thygeson, MD Associate Medical.
Innovations in Reducing Cost & Improving Quality of Health Care Donald S. Furman, M.D. ~ Chief Medical Advisor CAREMORE “It’s what we do”.
Value Based Insurance Design Michael Chernew Feb 22, 2008 Portions of this research were funded by Pfizer and GSK.
PEEHIP Wellness Program New and Enhanced!. PEEHIP Wellness Program  Fact: According to the US Department of Health and Human Services, chronic diseases.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
It’s A Success! Achieving Cost-Effective Disease Management in CHF Sherry Shults, RN BSN CIO South Carolina Heart Center.
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
Prescreening ä To optimize safety ä To permit the development of a sound and effective exercise prescription.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
APPENDIX 1. D-1 New cases of diagnosed diabetes D-2.1 All cause mortality* D-2.2 Cardiovascular disease deaths* D-3 Diabetes death rate, multiple cause.
DIABETES With All My Heart Presented by: Regina Weitzman, MD.
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
... a KAISER PERMANENTE Innovation IndiGO: Tailoring Guidelines to Individuals David M Eddy MD PhD Founder and Chief Medical Officer Emeritus Archimedes.
HYPERTENSION The Alabama Department of Public Health’s Hypertension Program.
Heart Health Project University of Pennsylvania School of Medicine American Heart Association Pennsylvania State University Funded by the Robert Wood Johnson.
British Journal of Healthcare Assistants The HCAs Role in Diabetes Management in Primary Care Linda Goldie Clinical Director Primary Care Training Centre.
The BIPA Disease Management Demo Project: Improving Outcomes For Medicare Beneficiaries Prepared for: Disease Management Colloquium June 29, 2004 The BIPA.
RHI - Confidential and Proprietary - Do Not Copy Improving Health Care Quality and Cost Effectiveness Dean Souleles Chief Operating Officer November 21,
Community Health Team Care Management Process PinnacleHealth Systems Don DeArmitt, M.D. Becky E. Zook RN, BSN, MS, CCP.
IMPROVING DIABETES CARE FOR ADULTS: A Population-Based Approach Patrick J. O’Connor, MD, MPH Senior Clinical Investigator HealthPartners Research Foundation.
Session II: Glycemic control, when the lower is not the better Strict glycemic control and cardiovascular diseases Stefano Genovese Diabetologia e Malattie.
Microsoft’s Wellness & Weight Management Programs December 14, 2005 Tom McPherson Senior Benefits Manager.
Unique & Creative Plan Design Suggestions to Help Control Costs
Medication Adherence The following module is designed as a basic overview of medication adherence for providers of healthcare, particularly those in a.
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.
New Approaches to Disease Management Get Connected Knowledge Forum Larry G. Anderson MD MMC Physician-Hospital Organization June, 2005.
Together.Today.Tomorrow. The BLUES Project Karen C. Fox, PhD Chief Executive Officer.
Worksite Wellness 1 Medical costs fall by an average of $3.27 for every dollar spent on employee wellness programs.
Innovations in Management of Cardiovascular Disease for Global Health
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
January 2013 Webinar: “Practical Ways to Help Get Our Diabetes Patients to Goal” Controlling the ABC’s Cases.
Disease Management & Pay-for-Performance: Is it just about the money? June 22, 2005 Harry L. Leider, MD, MBA Chief Medical Officer, XLHealth.
Health Promotion and Wellness GNRS 5521: Clinical Role Practicum Case Presentation by Elizabeth Lopez On January 27, 2014 ____________________________________________.
Improving Clinical Processes: The Million Hearts ® Hypertension Control Change Package for Clinicians Erica K. Taylor, PhD, MPH, MA Million Hearts ® Minority.
NHS Health Checks Helping you prevent heart disease, stroke, diabetes and kidney disease.
Disease Management & Special Needs Plans May 11, 2006.
CONFIDENTIAL & PROPRIETARY Expanding the Reach of Predictive Models: Using Clinical, HRA, and Consumer Data Dan Dunn, PhD, Senior VP of R&D, Ingenix The.
Health Reform: The Role of Chronic Care and Primary Prevention Kenneth E. Thorpe, Ph.D. Robert W. Woodruff Professor and Chair Department of Health Policy.
HOUSTON METHODIST POPULATION HEALTH MANAGEMENT
ASSOCIATED CONDITIONS WITH DIABETES MELLITUS TYPE II.
The Role of Health Information Technology in Implementing Disease Management Programs Donald F. Wilson, MD Medical Director Quality Insights of Pennsylvania.
Wellness Coalition America Fully Integrated Solution April 2014.
Manatee County Utilities Department Manatee County Administrator’s Office Carrots and Sticks : Approach to Controlling Health Care Costs and Creating a.
100 years of living science Chronic disease management in primary care: lessons to be learnt Dr Shamini Gnani November 2007, Mauritius.
PUTTING PREVENTION FIRST Vascular Checks Dr Bill Kirkup Associate NHS Medical Director.
PUTTING PREVENTION FIRST Vascular Checks/ NHS Health Checks.
Estimating Absolute Risk Reductions Associated with Interventions in Patients with Type 2 Diabetes Jim Mold, M.D., M.P.H. Brian Firestone, MS2.
Bariatric Surgery for T2DM The STAMPEDE Trial. A.R. BMI 36.5 T2DM diagnosed age 24 On Metformin, glyburide  insulin Parents with T2DM, father on dialysis.
Management of Hypertension according to JNC 7
Medication therapy management
Bending the Cost Curve A Case for Integration.
Diabetes Health Status Report
Improving Chronic Care Management
Macrovascular Complications Microvascular Complications
Presentation transcript:

Enhancing Care Management of the Chronically Ill Through Medication Management and Adherence Harry Leider, MD, MBA, FACPE Chief Medical Officer XLHealth and Care Improvement Plus

2 Background on XLHealth Founded in 1998 as a DM company focused on diabetes Participated in BIPA and MHS CMS DM demos In 2006, launched a Chronic Care Special (C-SNP) Needs Plan pilot in Maryland –Traditional health plan structure, plus Part D, plus DM programs In 2007, withdrew from DM vendor business and launched Chronic Care Special Needs Plans in 6 states –65,000 seniors –All have either: heart failure, diabetes, COPD, ESRD We now have full financial risk for each member –Averages $15,000 per member

3 Leveraging medication data and use is a critical part of our business 1.Our members average 6 chronic medications 2.Medication spending is over 18% of our total medical spend 3.Providing access to key meds is a important aspect of our health plan value proposition to seniors 4.Achieving adherence with key medications drives outcomes in our DM programs

4 Objectives 1.To provide an overview of how chronic care plans can use medication “benefit design” to improve enrollment and DM outcomes 2.To examine how medication utilization data can be leveraged to improve DM outcomes 3.To examine new technology-based tools for improving medication adherence 4.Questions and Discussion!

5 Plan Formulary Design: Our Concept of “Tier 5” drugs While we do have traditional co-pays in our Part D plan Our member have access to our “Tier 5 drugs” at zero cost through the “donut hole” Examples include: –Beta-blockers (brand), TZDs, spironolactone, nsulin, diuretics, ACE The objective: improve access and adherence A growing concern about shifting costs of drugs to patients and reducing access….

6 The Value of Drug Utilization Data 1.To enhance patient identification 2.Basic risk stratification for DM Programs 3.More sophisticated predictive modeling 4.Targeting opportunities for care management

7 The Value of Drug Utilization Data 1.Patient Identification/basic risk stratification for DM Programs Spironolactone: severe Heart Failure Oral Steroids in adults with COPD

8 The Value of Drug Utilization Data 2.Basic Risk Stratification Principle: Patients with chronic illness who are not on key medications have an increased risk of hospitalization and death…..

9 Medication Management in Diabetes: 7-Year Outcomes Adapted from Haffner SM, et al. N Engl J Med. 1998;339: Relative 25% 25% 20% 20% 15% Risk Diabetes + prior MI Diabetes w/o prior MI 45% 14% 6% 20% No RxStatinHTNASAFibrate TZD Metformin Glucose Control CVD Mortality

10 The “Quick Hits” in Diabetes ASA Lipids ACE/ARBs BP control Beta-blockers in patients with prior MI Glycemic control in patients with HgbA1C > 9 or 10*

11 Is it all about “Better Living Through Chemistry?” What about changing lifestyle issues? These issues are important BUT are very hard to change! Getting patients to diet, lose weight, exercise, and stop smoking after MANY years of bad habits is very difficult! Strategy: –Focus first on the quick hits! (mostly medications) –Then work on lifestyle issues

12 3.Medications and Predictive Modeling

13 Archimedes TM : Predictive Model Based on 18 high quality diabetes outcomes studies Predicts 30 year risk of heart attacks, strokes, kidney failure, amputations, eye disease Model requires –Demographics information –Risk factors –Lifestyle issues –Some physical measurements (BP) –Some lab data (LDL, HDL, total cholesterol, alb/creat) –Meds for diabetes, hypertension, and hyperlipidemia You can change risk factors and see the impact on risk of a future outcome!!!

14 Patient Profile: Harry 2 74 y.o. black male, obese, Type II DM, hypertensive (not controlled), moderately elevated lipids

15 Health History Risks in addition to demographics, BP, and Lipids

16 Current Meds for DM, HTN, Lipids (insulin added to the model)

17 Overview: 30 Yr. Risk of Major Health Outcomes

18 Heart Attack risk (baseline): 45% over 10 years (on ACE already)

19 Impact of Aggressive Lipid Management and Aspirin Risk over 10 years reduced from 45% you 25% !!!!

20 Additional Impact of Control of Moderate Hypertension Minimal additional impact of control of moderate hypertension after ASA and lipid control

21 Impact of Increased Glycemic Control MI risk decreased further from 25% to 20% over 10 years

22 Impact of smoking cessation (after other risk factors modified) Risk of MI reduce >5% by smoking cessation even after lipid and HTN control, use of ASA and tight glycemic control

23 Improving Adherence and Outcomes Medications are the most powerful interventions in many chronic conditions Two key drivers of outcomes –Putting patients on key drugs –Optimal levels of adherence Key barriers to adherence: –Patient’s can’t afford the medications –Failure to take the medications regularly

24 Health Care Costs Negatively Impact Adherence

25 Generics Can Reducing Drug Costs and Improve Adherence

26 IVR Generic Switching Outreach End of Campaign Summary January 2008

27 Goals  Encourage members to switch to a generic alternative/equivalent of the drug they have been prescribed Targets  XLHealth members who are currently taking either a cholesterol drug or PPI Generic Switching Outreach

28 Generic Switching Outreach Outreach Process Overview  Confirm target member  Explain that there are low cost alternatives for current medications  Review specific savings with members who allow IVR to mention the name of drug they are taking  Review general savings with those members who do not allow the script to mention the names of the drug they are taking  Review the generic alternatives/equivalents for the drug the member is currently taking  Offer to transfer the member to a representative for more specific information regarding available savings

29 Generic Switching Outreach Key Outcomes: Total Population: We received 16,105 records; 4.43% of records were scrubbed, leaving us with a Target Population of 15,391 members to reach out to. Targets Reached: We were able to reach 58% of target members. Typically, we see about 50% for a campaign with two rounds of outbound calls. Yes to Continue: Close to our benchmark of 75%, 70% of the target members reached asked to continue with this call, showing the great interest in hearing more information about savings Hang Up Rate: At 5%, as compared to our benchmark of 10% or less, we feel that this, once again, shows a strong member affinity towards XLHealth and Care Improvement Plus.

30 ♦ Simple - used successfully by Seniors with 5 th Grade Education ♦ Manages 25 medications per patient and delivers education, questionnaires, behavioral prompts, reminders ♦ Branching logic captures critical health information ♦ Customized – Web-based individualized care plan ImforMedix Med-eMonitor

31 Confidential and Proprietary XLHealth/InforMedix/ADT Workflow Process

32 Confidential and Proprietary Remote Monitoring Process:

33 Summary Medications play a critical role in a chronic care SNP (and in all DM programs) A specific opportunity in the C-SNP model is innovative benefit design to reduce co-pays and improve access “Driving” patients to generics is important to increase adherence and reduce costs Drug data can help identify and risk stratify patients for DM programs New technologies are showing promise for improving medication therapy and adherence

34 Discussion and Questions?